Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is a clinical-stage biopharmaceutical company whose news flow centers on the development of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, and related immunomodulation programs. Company announcements highlight progress in neuroinflammatory and neurodegenerative indications, including non-active secondary progressive multiple sclerosis, early Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS).
News about Tiziana often covers key clinical milestones. Recent releases describe dosing of patients in a Phase 2 randomized, placebo-controlled trial of intranasal foralumab in early Alzheimer’s disease, including evaluation as monotherapy and in combination with FDA-approved anti-amyloid therapies lecanemab and donanemab. Other updates report on the Expanded Access Program in non-active secondary progressive multiple sclerosis and the acceptance of the company’s ALS Phase 2 trial into the ALS MyMatch Program at the Sean M. Healey & AMG Center for ALS.
Investors following TLSA news can also expect regulatory and safety updates, such as the submission of Development Safety Update Reports to the U.S. Food and Drug Administration, which summarize cumulative exposure and safety findings for intranasal foralumab. Corporate and capital markets news includes insider share purchases by senior leadership, decisions regarding proposed public offerings, and participation in industry conferences like BIO-Europe, the Jefferies London Healthcare Conference, and neuroscience-focused forums.
This news page aggregates these company-issued press releases and related coverage, giving readers a centralized view of Tiziana’s clinical progress, regulatory interactions, strategic initiatives such as the planned spinout of IL-6 asset TZLS-501, and visibility events like ringing the Nasdaq Closing Bell. Users interested in TLSA can review this feed to monitor how Tiziana’s immunotherapy and drug delivery programs evolve over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Tiziana Life Sciences (TLSA) recently announced significant findings on the utilization of intranasal anti-CD3 monoclonal antibodies (mAb) for treating intracerebral hemorrhage (ICH) at the Annual American Academy of Neurology conference. ICH, with a mortality rate of 30% to 40%, currently has no effective treatments. The study demonstrated that intranasal foralumab significantly reduced ICH injury severity, improved motor coordination, memory retention, and accelerated hematoma resolution. It also showed a reduction in neuronal cell death and blood-brain barrier leakage. Gabriele Cerrone, the CEO, emphasized the potential of foralumab in neuroinflammation treatment, paving the way for broader applications and potential shareholder value creation. Phase 2 trials are expected to begin in Q3 2023.
Tiziana Life Sciences (Nasdaq: TLSA) reported its financial results for 2022, showing a loss of $19.0 million, improved from $27.9 million in 2021. R&D expenses slightly decreased to $13.0 million primarily due to focusing on foralumab. The company ended 2022 with $18.1 million in cash. Tiziana is prioritizing intranasal foralumab for treating CNS-related inflammatory diseases, including Alzheimer’s and Type 1 diabetes. It plans to file an IND for Alzheimer’s trials by Q2 2023 and has reported positive developments in its Expanded Access Program for multiple sclerosis. Tiziana's intranasal foralumab has been recognized in major medical publications and is anticipated to enter Phase 2 studies this year.
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) has announced that it has regained compliance with Nasdaq's minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company was previously notified on June 14, 2022, of its non-compliance due to its stock closing below $1.00 for 30 consecutive business days. Tiziana successfully maintained a closing bid price of $1.00 or more for at least ten consecutive trading days, achieving compliance as of April 20, 2023. The company is focused on developing innovative immunomodulation therapies, particularly through its lead candidate, intranasal foralumab, which aims to improve efficacy and safety compared to traditional intravenous therapies.
Tiziana Life Sciences Ltd. (TLSA) announced plans to submit an IND for intranasal foralumab in Alzheimer’s patients during Q2 2023, following FDA Type “B” meeting feedback. The company seeks $3M in non-dilutive funding from an Alzheimer’s foundation to support a Phase 2a trial aimed at assessing the drug’s effects on neuroinflammation related to microglia activation.
The study aims to administer intranasal foralumab over three months to evaluate its potential in restoring the neuroinflammatory activated state of microglia in Alzheimer’s patients. There are currently no approved treatments for neuroinflammation specifically triggered by amyloid beta plaque.